Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna Collaborates With Catalent for Coronavirus Vaccine

by Zacks Equity Research

Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.

Ritujay Ghosh headshot

3 Stocks to Buy as Companies Speed Up Vaccine Production

by Ritujay Ghosh

Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.

Kevin Cook headshot

Bull of the Day: Quidel (QDEL)

by Kevin Cook

Multiple FDA approvals for new 15-minute COVID-19 antigen tests have estimates and shares rising sharply

Neena Mishra headshot

Invest in the Future With Megatrend ETFs

by Neena Mishra

These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.

Zacks Equity Research

Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Sweta Killa headshot

New GERM ETF Launched to Tap the Growing Biotech Sector

by Sweta Killa

GERM invests in the hottest emerging biotechnology trends.

Zacks Equity Research

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $63.31 in the latest trading session, marking a -1.6% move from the prior day.

Zacks Equity Research

Novavax (NVAX) Up More Than 1200% Year to Date: Here's Why

by Zacks Equity Research

Novavax's (NVAX) coronavirus vaccine candidate NVX-CoV2373 enters clinical studies. The company also plans to file a BLA on its influenza vaccine candidate, NanoFlu.

Zacks Equity Research

Vaxart Gets New CEO, Focuses on Coronavirus Vaccine Program

by Zacks Equity Research

Vaxart (VXRT) management names Andrei Floroiu as its next chief executive officer with immediate effect. Stock appreciates on this news.

Ekta Bagri headshot

3 Big Biotechs Poised for Growth Amid Coronavirus Pandemic

by Ekta Bagri

We highlight a few leading players from the biotech sector, who are likely to see a good run as the year progresses.